Fractyl Health to Present at BofA Securities 2024 Health Care Conference
May 08, 2024 06:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
May 07, 2024 06:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
April 30, 2024 08:38 ET
|
Fractyl Health, Inc.
Fractyl Health Announces Multiple Presentations at DDW 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
April 02, 2024 08:00 ET
|
Fractyl Health, Inc.
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation
Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes
March 14, 2024 04:14 ET
|
Atrogi
SOLNA, Sweden, March 14, 2024 (GLOBE NEWSWIRE) -- Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces the full set of results from its Phase 1...
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
March 12, 2024 14:06 ET
|
Fractyl Health, Inc.
Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
March 12, 2024 08:38 ET
|
Fractyl Health, Inc.
Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
February 20, 2024 08:38 ET
|
Fractyl Health, Inc.
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
Fractyl Health Announces Pricing of Initial Public Offering
February 01, 2024 20:08 ET
|
Fractyl Health, Inc.
Fractyl Health (Nasdaq: GUTS), announces pricing of initial public offering.
Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in Its Rejuva® GLP-1 Gene Therapy Platform
January 05, 2024 07:48 ET
|
Fractyl Health, Inc.
FRACTYL HEALTH ANNOUNCES NOMINATION OF RJVA-001 AS FIRST CLINICAL CANDIDATE IN ITS REJUVA® GLP-1 GENE THERAPY PLATFORM